TP53 and mantle cell lymphoma: Other venues of development include ambitions to develop response adapted treatment strategies, based on MRD66; incorporation of the new knowledge emerging from biology studies into risk-based strategies, specifically targeting biological high-risk populations such as TP53-mutated MCL; strategies to improve outcome for BTKi-refractory disease; as well as real-world evidence studies, based on the high quality, nation-wide registers present in many European countries.